echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Eur Heart J: Lipoprotein (a), LDL-C, and hypertension are predictive factors for aortic valve replacement in FH patients

    Eur Heart J: Lipoprotein (a), LDL-C, and hypertension are predictive factors for aortic valve replacement in FH patients

    • Last Update: 2021-01-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Familial hypercholesterolemia (FH) and lipoprotein (a) (Lp(a)) elevations are genetic disorders associated with premature atherosclerosis cardiovascular disease (ASCVD).
    aortic valve stenosis (AVS) is the most common valve heart disease, and low-density lipoprotein cholesterol (LDL-C) and Lp(a) may be involved in their pathophysiological mechanisms.
    , researchers looked at the frequency and predictor of severe AVS in patients with FH who need aortic valve replacement (AVR), according to a recent study published in Eur Heart J, an authoritative journal in the field of cardiovascular medicine.
    SAFEHEART study is a long-term prospective cohort study of FH populations and uninfed relatives (NAR).
    researchers analyzed the frequency and predictive factors of AVR needed in the queue due to AVS.
    the study, 5,222 subjects were selected (3,712 FH; NAR 1,310).
    50 FH patients (1.48%) and 3 NAR patients (0.27%) needed AVR (ratio of 5.71; 95% confidence interval (CI): 1.78-18.4;
    AVR was significantly higher in patients with FH (log-rank=5.93; P=0.015).
    Cox regression analysis shows an association between FH and AVR (risk ratio: 3.89; 95% CI: 1.20-12.23; P=0.024), older, past ASCVD, hypertension, LDL-C elevation, and independent predictors of Lp(a) elevation events.
    result, there has been a significant increase in AVR demand for AVS in FH patients, especially those who are older and have previously suffered from ASCVD, high blood pressure, elevated LDL-C, and elevated Lp(a).
    LDL-C and Lp(a) and the control of hypertension may delay AVS progression in FH patients, but this needs to be tested in clinical trials.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.